2017 Autumn Conference includes Joint Day with ECNP
31 August – 02 September, 2017 // Le Meridien Etoile, Paris, FR
Distinguished Poster Award Recipients: |
||
| Effect of High within Subject Variance at Research Sites on Placebo Response and Drug Placebo Separation in Acute Schizophrenia Trials – A Post Hoc Analysis (Kott)
Replication of a Statistical Method to Reduce Pseudospecificity and Enhance Understanding of Score Changes Among PANSS Factors (Mahableshwarkar) |
||
|
All Poster PDFs and Abstracts are available at the end of the second day. |
||
31 August 2017 |
||
| Welcome Reception | ||
1 September 2017
|
||
| Welcome from the Presidents | S Marder slidesC Arango slides video |
|
| Beyond Efficacy: Hard Outcomes in Treatment Studies | Chairs: N Schooler G Goodwin |
|
| Introduction | G Goodwin slides video |
|
| Within-subject comparison as a tool to explore effectiveness in register studies | M Landén slides video |
|
| Relapse prevention studies: What happens after drop out? | S Leucht slides video |
|
| Industry Perspective: Risk characterization utilizing external data sources: A methodological consideration for clinical trials with high subject drop-out | J Geier slides video |
|
| Regulatory Comment/Panel Audience Discussion | M Tome video Speakers video |
|
| Clinician Reported Outcomes in Multinational CNS Trials: Practical Guidance on Translation and Cultural Adaptation | Chairs: A Kalali E Vieta |
|
| Introduction and background | A Kalali video |
|
| The impact of language and culture on implementing multinational clinical trials | M Vance slides video |
|
| Cultural learnings implementing multinational clinical trials | E Vieta slides video |
|
| Guidance document – overview and highlights | E Pappadopulos slides video |
|
| Panel and audience discussion | Speakers video |
|
| Drug Development for Negative Symptoms in Schizophrenia: What Have We Learned? What Can We Do Better? | Chairs: D Umbricht C Arango |
|
| Welcome and introduction | D Umbricht video |
|
| Negative symptoms: Prevalence, specificity, course and other characteristics | M Weiser slides video |
|
| Preclinical models of negative symptoms and their implications for clinical trials | M Kas slides video |
|
| Negative symptoms: Clinical assessments, biomarkers and the role of reward processing | J Gold slides video |
|
| Lessons learned in recent trials in negative symptoms | D Umbricht slides video |
|
| Conclusion and next steps | J Lieberman slides video |
|
| Panel discussion/Regulatory Comment | Moderator: J Lieberman video |
|
| Concluding remarks | C Arango |
|
| Joint meeting adjournment | S Marder C Arango video |
|
| ISCTM Poster Session | Poster PDFs and Abstracts | |
2 September 2017 |
||
| Behavioral and Psychiatric Symptoms in Dementia (BPSD): A Way Forward? | Chairs: L Ereshefsky L Pani |
|
| Background, brief overview and session’s purpose | L Ereshefsky L Pani |
|
| Segment 1- Agitation in Alzheimer’s Disease | ||
| Lessons Learned – Part One – Agitation in Alzheimer’s Disease – Progress in Trials Designs | B Creese slides video |
|
| Lessons Learned – Part Two – Agitation in Alzheimer’s Disease – Developing New Treatments | P Rosenberg slides video |
|
| Comments from Industry Perspective | S Dube slides video |
|
| Regulatory Viewpoints – Agitation in AD | V Mantua slides video T Farchione slides video |
|
| Panel – Audience discussion – Agitation in AD | Facilitators: J Rasmussen J Bell Agitation Panel video |
|
| Segment 2 – Apathy in Alzheimer’s Disease | ||
| Why focus on apathy? Diagnosis, symptoms assessment, methodology framework | D Miller slides video |
|
| Neuro-circuitry and implications for drug development: ADMET trials, and study designs for treatment of apathy | K Lanctot slides video |
|
| Quantifiable assessment of motivational deficits and apathy in dementia – and beyond | S Pollentier slides video |
|
| Treatment of apathy in psychiatry and neurodegenerative disorders: Are positive valence systems of reward shared in common? Early drug development implications | L Ereshefsky slides video |
|
| Concluding Discussant | Discussant: L Pani slides video |
|
| Regulatory Viewpoints/Panel – Audience discussion – Apathy in AD | Facilitators: L Ereshefsky S Pollentier Panel: T Farchione V Mantua slides Apathy speakers video |
|
| Meeting Adjourns | S Marder | |